HBsAg plasma level kinetics:a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy by Carey, I et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/jvh.12316
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Carey, I., Bruce, M., Horner, M., Zen, Y., D'antiga, L., Bansal, S., ... Mieli-vergani, G. (2015). HBsAg plasma
level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on
combination therapy. Journal of Viral Hepatitis, 22(4), 441-452. 10.1111/jvh.12316
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
 1 
 
HBsAg plasma level kinetics: a new role for an old marker as a therapy 
response predictor in vertically infected children on combination therapy 
 
Ivana Carey*, MD PhD1,2,3  
Matthew Bruce, MSc2 
Mary Horner, MSc2 
Yoh Zen, MD2 
Lorenzo D’Antiga, MD4 
Sanjay Bansal, MD4 
Diego Vergani, MD PhD1,5 
Giorgina Mieli-Vergani, MD PhD1,4,5 
 
 
Institute of Liver Studies and Paediatric Liver, GI & Nutrition Centre, King’s 
College London School of Medicine at King’s College Hospital, Denmark Hill, 
London SE5 9RS, UK  
 
Involvement of authors in the study:  
1 - study concept and design 
2 - acquisition of data 
3 - analysis and interpretation of data, statistical analysis, manuscript drafting  
4 - medical care 
5 – obtaining funding, study supervision 
 2 
* Address for correspondence: Ivana Carey, Clinical Lecturer in Viral Hepatitis, 
Institute of Liver Studies, King’s College Hospital, Denmark Hill, London SE5 9RS, 
UK, Tel: +44 20 32994313; Fax: +44 20 3299 3899; E-mail: 
ivana.carey@btinternet.com 
Abstract word count: 250 
Manuscript word count: 4046 
 
No conflicts of interest exist for all authors.  
The study was supported by Wellcome Trust grant WT 055164MF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
ABSTRACT 
We aimed to investigate the ability of HBsAg plasma level kinetics to predict 
therapy response by studying 23 children with infancy-acquired chronic hepatitis 
B (CHB) during combination sequential therapy with lead-in lamivudine (LAM) 
and add-on interferon- (IFN-) [5 responders (R=anti-HBs seroconversion) and 
18 non-responders (NR)] and to assess their relationship with pre-treatment 
intrahepatic HBV-DNA and cccDNA and HBsAg and HBcAg liver expression. 
Methods: Plasma HBsAg levels were measured in samples before (treatment 
week 0=TW0), during (TW9, TW28, TW52) and after (follow-up week=FUW24) 
therapy by Abbott ARCHITECT® assay [log10IU/ml]. Baseline liver HBV-DNA and 
cccDNA were quantified by real-time TaqMan PCR [log10copies/ng genomic 
DNA]. HBsAg and HBcAg liver expression was evaluated by immunostaining of 
formalin-fixed, paraffin-embedded specimens [number of positive cells/1000 
hepatocytes]. All results are presented as medians. 
Results: Plasma: at baseline, on-treatment and during follow-up, HBsAg levels 
were lower in R than NR (TW0: 4.36 vs. 4.75;TW28: 2.44 vs. 4.35;TW52: 0 vs. 
4.08 and FUW24: 0.17 vs. 4.35, all p<0.05). Liver: baseline HBV-DNA (3.82 vs. 
4.71, p=0.16) and cccDNA (1.98 vs. 2.26, p=0.18) tended to be lower in R than 
NR, HBsAg expression was lower in R than NR (0.5 vs. 4.7, p=0.03) and HBcAg 
expression was similar between R and NR. There were positive correlations 
between plasma HBsAg levels and liver HBV-DNA (r=0.44,p=0.04), cccDNA 
(r=0.41,p=0.04) and HBsAg liver expression (r=0.38,p=0.05). 
Conclusions: Lower baseline HBsAg plasma levels, lower HBsAg expression in 
liver and on-treatment decline of plasma HBsAg levels heralds HBsAg clearance 
and response to treatment in tolerant children with CHB.      
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INTRODUCTION 
Approximately 400 million people worldwide are chronically infected with 
hepatitis B virus (HBV) resulting in over 1 million related deaths per year [1-2]. 
HBsAg clearance is the ultimate goal of antiviral therapy for HBV infection [3]. In 
plasma HBsAg circulates in variable forms, namely as a part of mature virions 
enveloping viral DNA (42nm size Dane particles) or as non-viral (subviral) 
particles, i.e. 20 nm diameter filaments and 20-22 nm size spherical defective 
particles corresponding to empty viral envelopes [4-7]. HBsAg plasma levels and 
HBsAg kinetics during antiviral therapy with pegylated interferon or/and 
nucleos(t)ide analogues has become a clinical tool for monitoring on-therapy 
response in adults, as recommended by  NICE guidelines [8-13, 31]. No data are 
available on children. 
Acquiring HBV infection perinatally leads to HBV persistence, characterised 
by a prolonged immunotolerant phase of disease during childhood [1-2,13-14].  
Data from two cross-sectional studies in adults demonstrated HBsAg plasma 
levels to be higher in the immunotolerant phase than in the immunoactive phase of 
HBeAg positive (HBeAg+) chronic hepatitis B (CHB) infection, suggesting that high 
HBsAg levels are involved in promoting immune tolerance [9-15]. While a few 
studies have evaluated HBsAg decline during combination therapy with 
nucleos(t)ide analogues and pegylated IFN- commenced simultaneously in adult 
HBeAg+ CHB [23-30], there are  no data on HBsAg kinetics during sequential 
lead-in therapy with nucleos(t)ide analogue followed by add-on IFN- and its 
impact on predicting therapy responses in immunotolerant children.  
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HBV-DNA replication and HBsAg secretion pathways are distant 
processes within hepatocytes. It is suggested that HBsAg plasma levels reflect 
transcriptional activity of covalently closed circular DNA (cccDNA) activity rather 
than total liver cccDNA content [6-8]. Translation of HBsAg depends on 
transcription of the appropriate mRNAs from cccDNA [32]. cccDNA acts as a 
transcriptional template of HBV within the nucleus and represents the 
intrahepatic reservoir for HBV; cccDNA concentrations reflect different stages of 
CHB infection [11,16, 33-37]. Correlations between HBsAg plasma levels, liver 
relaxed circular (RC) HBV-DNA and cccDNA have been demonstrated in 
HBeAg+ CHB patients [11,16]. Additionally, a relationship between cccDNA and 
hepatitis B core antigen (HBcAg) has been reported [38], but no data are 
available on the association between HBsAg and HBcAg expression in the liver, 
intrahepatic cccDNA and HBsAg plasma levels in immunotolerant perinatally 
infected children [38].  
Therapy response has also been shown to be influenced by HBV 
genotypes and presence/absence of changes within the basal core promoter 
(BCP) and pre-core region (stop codon 1896), changes in BCP and/or pre-core 
regions being linked with poorer response in adult patients with active disease 
[39]. 
We have investigated longitudinally plasma HBsAg kinetics and their 
relationship with plasma HBV-DNA and with pre-treatment levels of liver RC 
HBV-DNA and cccDNA and expression of liver HBsAg and HBcAg in tolerant 
children during antiviral therapy with lead-in lamivudine and add-on interferon-α. 
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The importance of HBsAg kinetics and changes in BCP and pre-core regions on 
predicting therapy response were also evaluated.  
PATIENTS  
Twenty-three children with perinatally acquired CHB, treated with 
combination antiviral therapy, were investigated (Table 1). They were all HBeAg+, 
HBV-DNA positive, and all but 2 had persistently normal transaminases levels. 
Their pre-treatment liver biopsies showed minimal/mild inflammation and no 
fibrosis. Patients were treated for 52 weeks in total; initially lamivudine lead-in (3 
mg/kg/day) was administered once daily on its own for 8 weeks and for a further 
44 weeks in combination with add-on interferon-α (IFN-α) 2b (5MU/m2 
subcutaneously), given daily for the first 5 doses [treatment week 9 (TW9)] and 
then thrice weekly for the remaining 44 weeks [40]. The informed written consent 
to participate in the study was obtained from patients’ legal guardians and the 
study was conducted following the principles of the World Medical Association 
Declaration of Helsinki. 
 Clinical and laboratory monitoring is summarized in Figure 1. Sustained 
virological response (SVR) was defined as decline of HBV-DNA below detection 
limits of quantitative real-time polymerase chain reaction (PCR) assay (20 IU/ml) 
and anti-HBe seroconversion lasting for >6 months after antiviral therapy 
discontinuation; complete response was defined as normal aminotransferase 
levels, HBeAg seroconversion, decrease of HBV-DNA below 20 IU/ml, loss of 
HBsAg, anti-HBs seroconversion persisting during the 5-year follow-up period [40]. 
At treatment-end (TW52), 5 patients were anti-HBe positive, 4 of whom were also 
HBsAg negative/anti-HBs positive (all genotype B). During follow-up [follow-up 
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week 52 (FUW52)], the fifth patient (genotype A) seroconverted to anti-HBs. These 
five children are defined as ‘responders’. Two further patients (both genotype D) 
seroconverted to anti-HBe 36 and 48 months after treatment-end, but their HBV-
DNA remained above 2000 IU/ml. Two children with mildly abnormal baseline 
transaminases levels did not respond to treatment. No lamivudine-related 
mutations were detected during therapy and follow-up. 
Controls included 7 untreated HBeAg+ children with perinatally acquired 
CHB (Table 1) with minimal/mild inflammation and no fibrosis on liver biopsy, and 
assessed regularly every 6 months during a 2-year follow up period.   
 
MATERIALS AND METHODS 
Materials  
Plasma samples were obtained at baseline, during and after antiviral 
therapy at different time-points (Figure 1). Liver biopsy was performed in all 
patients prior to starting antiviral therapy.  
Methods 
HBV serological markers 
Hepatitis B envelope antigen (HBeAg), antibodies against HBeAg (anti-
HBe), hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs) 
were evaluated using commercially available enzyme immunoassays (MEIA, 
Abbott, USA). 
HBV-DNA viral load quantitation  
Plasma concentrations of HBV-DNA were determined by a commercially 
available quantitative real-time polymerase chain reaction (PCR) assay, the 
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COBAS AmpliPrep-COBAS Taqman HBV test (CAP-CTM; Roche Molecular 
Systems Inc., Branchburg, NJ, USA) with a lower detection limit of 20 IU/ml. The 
results are presented as log10IU/ml. 
HBsAg quantitation assay 
Plasma HBsAg levels at different therapy time-points were measured 
using the Abbott ARCHITECT® HBsAg chemiluminescent microparticle 
immunoassay (CMIA) (Abbott Diagnostics, Abbott Park, IL, USA). The test has a 
dynamic range of 0.05-250 IU/ml. Samples were initially diluted 1:500 according 
to the manufacturer’s instructions. Samples with HBsAg levels less than 25 IU/ml 
were retested neat. The results are presented as log10IU/ml [4-5]. 
HBV genotypes, YMDD and HBV pre-core region mutation testing 
HBV genotypes and HBV polymerase YMDD mutation were determined 
by direct sequencing of PCR-amplified DNA fragments from the pre-S1/pre-S2 
and S gene and overlapping polymerase gene regions [41] and compared with 
known sequences. To identify mutations within the BCP region and 1896 stop 
codon, the purified and sequenced PCR products were compared with known 
sequences at codons 1762, 1764 and 1896.   
HBV-DNA isolation from liver 
HBV-DNA in liver was isolated from ~1-2mm of tissue as previously 
described [42].  
Real-time PCR for HBV-DNA quantitation in liver 
 HBV-DNA viral load in liver (RC HBV-DNA) was quantified by real-time 
TaqManTM PCR [41]. The concentration of liver genomic DNA was determined by 
QuantifilerTM Human DNA quantification kit [Applied Biosystems, Foster City, CA, 
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USA (AB)].  Liver DNA was amplified with 2 primers and the HBV probe labelled 
with fluorophore 6-carboxyfluorescein (FAM) and non-fluorescent quencher (AB) 
using ABI PRISM 7000 SDS Software (AB) as described previously [38]. HBV 
concentration was determined using a 12-point standard curve generated with 
plasmid pHBV991 (1010-1 copies/ml), and results were expressed as log10 number 
of HBV-DNA copies per ng of liver genomic DNA. Intra-assay coefficient of 
variation (CV) for triplicate experiments was 0.25-1.04%; the inter-assay CV, 
determined on eight samples in 6 different runs, 0.32–0.98%. 
Real-time PCR for cccDNA Quantitation 
 Liver HBV cccDNA was quantified by real-time TaqManTM PCR after 
treatment of liver DNA with 25U ATP-dependent DNAase (PlasmidSafeTM, 
Epicentre, Madison, WI, USA) [38]. The digestion product containing HBV cccDNA 
was amplified in the presence of 2 primers and HBV probe labelled with FAM and 
tetramethylrhodamine (TAMRA) quencher as described previously [38]. cccDNA 
concentration was determined using a 12-point standard curve generated with 
plasmid pHBV991 (107–10-3 copies/ml). Concentration of liver genomic DNA was 
measured by QuantifilerTM Human DNA. Results are expressed as log10 number of 
cccDNA copies/ng of liver genomic DNA (detection limit 5x10-1 copies/ng), intra- 
and inter-experimental assay CV ranges being 1.34–2.21% and 0.62–1.93%. 
Immunohistochemical detection of HBcAg and HBsAg expression in the liver   
HBcAg and HBsAg expression within the liver was evaluated by 
immunostaining deparaffinised and re-hydrated sections of formalin-fixed, paraffin-
embedded liver specimens, using rabbit anti-HBc and monoclonal anti-HBs as 
primary antibodies and EnVision System anti-rabbit horseradish peroxidase as 
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revealing reagent for HBcAg and EnVision anti-mouse kit for HBsAg (all Dako, Ely, 
UK).  Number of positive cells expressing nuclear and/or cytoplasmic HBcAg and 
HBsAg per 1000 hepatocytes was scored semi quantitatively at 250x magnification 
[43]. 
Statistical Analysis 
Statistical analysis was performed using SPSS version 18.0 (SPSS Inc., 
Chicago, Illinois, USA). Continuous variables are presented as median and 
ranges and were compared using the Mann-Whitney test. Categorical variables 
were assessed using the Chi-squared or Fisher exact tests. Multivariate analysis 
was performed using linear regression analysis for continuous variables and 
binary logistic regression for categorical variables. Bivariate correlations between 
continuous variables were evaluated by Spearman’s rank test. P-values less than 
0.05 were considered significant. Sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were calculated using Bayes’ 
theorem.  
RESULTS  
Plasma HBV-DNA  
At baseline, HBV-DNA plasma levels (Figure 2A&B) were similar in 
responders and non-responders (median 8.21, range 7.03-8.68 vs. 8.13, range 
7.13-8.9 log10IU/ml). In responders HBV-DNA plasma levels declined significantly 
from TW9, persisting low throughout treatment, and remained below 2.5 
log10IU/ml at FUW24 (1.33, range 1.1-2.3 log10IU/ml) and below the limit of 
detection at FUW52 (Figure 2A). In non-responders levels of HBV-DNA were 
lower than baseline only at TW28 and TW52, returning to levels similar to 
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baseline at FUW24 and FUW52 (Figure 2B). A difference in HBV-DNA viral load 
between responders and non-responders became apparent from TW9 and 
persisted at TW28, TW52, FUW24 and FUW52 (Figure 2C). In 7 untreated 
patients HBV-DNA viral load did not change during the follow up period of 2 
years and was similar to the levels in treated patients at baseline (median 8.32, 
range 7.23–8.96 log10IU/ml) (Figure 2D).  
Plasma HBsAg levels  
At baseline, HBsAg levels were lower in responders than non-responders 
(Figure 3A&B) (median 4.36, range 3.64-4.64 vs. 4.75, range 3.74-5.10 
log10IU/ml, p=0.02) and the proportion of patients with HBsAg < 20 000 IU/ml 
=4.3 log10IU/ml was higher in responders vs. non-responders (60% vs. 22%, 
p=0.05). In responders HBsAg levels decreased significantly compared to 
baseline at TW28, remaining low throughout treatment and at FUW24 (0.17, 
range 0-1.1 log10IU/ml, p<0.01)  (Figure 3A). In non-responders HBsAg levels 
declined only slightly during treatment and returned to baseline values at FUW24 
(4.53, range 2.33-5.1 log10IU/ml) (Figure 3B). At end of therapy, HBsAg levels 
were undetectable in 4 out of 5 responders in contrast to none of the non-
responders. Only 2 of 18 non-responders had HBsAg levels below 2-log10IU/ml 
by the end of therapy (TW52). In 2 non-responders with HBsAg levels below 2.0-
log10IU/ml at TW52, HBsAg levels increased after stopping treatment (1.6 vs. 
4.41 and 1.67 vs. 4.22 log10IU/ml respectively). 
When compared to baseline, HBsAg plasma levels were similar at TW9 in 
responders and non-responders, but from TW28 HBsAg plasma levels declined 
markedly in responders and only slightly in non-responders (median difference –
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1.84 vs. –0.36, p=0.01) (Figure 3C). HBsAg levels persisted below 0.5-log10IU/ml 
in responders at TW52 and FUW24 (Figure 3A&C).  
In the seven untreated control patients baseline HBsAg levels were similar 
to those of treated patients and did not change throughout the follow up period 
(median 4.5, range 3.89–5.1 log10IU/ml) (Figure 3D). 
HBsAg plasma level kinetics  
According to changes in HBsAg plasma level kinetics between baseline 
and TW28 (i.e. after 20 weeks of IFN treatment), four different patterns of HBsAg 
plasma decline were seen: HBsAg decline >2-log10IU/ml (3 patients, all 
responders), HBsAg decrease <2-log10IU/ml, but >1-log10IU/ml (5 patients; 2 
responders and 3 non-responders), HBsAg reduction <1-log10IU/ml >0.5-
log10IU/ml (4 non-responders) and HBsAg decline <0.5-log10IU/ml (11 non-
responders). Among patients with a decline >1.0-log10IU/ml, 2 responders had 
baseline levels < 4.3-log10IU/ml, while levels were > 4.3-log10IU/ml in the 3 non-
responders. Only 4 non-responders, all with an HBsAg decrease  <1.0-log10IU/ml 
during treatment, had baseline HBsAg plasma levels < 4.3-log10IU/ml (Figure 4). 
All 3 patients with a decline > 2-log10IU/ml responded to therapy (PPV 100% and 
NPV 90%), while, 15 patients with a decline <1-log10IU/ml were non-responders 
(sensitivity 100%, specificity 83%, PPV 63% and NPV 100%). Two responders 
with reduction between 1-2-log10IU/ml by TW28 had lower baseline levels 
(median 4.08) in comparison to 3 non-responders with the same HBsAg kinetics 
(median 4.67) (p=0.03).  
Correlation between HBV-DNA and HBsAg levels in plasma 
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In treated patients there was no correlation between HBV-DNA and 
HBsAg plasma levels at baseline (r=0.35, p=0.1) in contrast to a strong positive 
correlation during therapy and follow-up (TW9: r=0.46, p=0.03; TW28: r=0.6, 
p=0.007; TW52: r=0.64, p=0.002 and FUW24: r=0.58, p=0.008) (Figures 5A-E). 
No bivariate correlations were noted in the untreated population at any time-
point. 
Hepatitis B genotype and changes in pre-core region (BCP and stop codon 
1896 mutations)  
HBsAg loss occurred in 4 out of 14 genotype B and 1 of 2 genotype A 
patients. No other genotypes were associated with HBsAg loss. Two genotype D 
patients had anti-HBe seroconversion more than 2-years after completing 
therapy. In responders, no changes within BCP (A1762T/G1764A) or stop codon 
1896 (G1896A) were present, while mutations were observed in 14 out of 18 
non-responders. Baseline changes within both BCP and stop codon 1896 were 
detected in 2 non-responders with genotype D who seroconverted to anti-HBeAg 
more than 2-years after stopping therapy.  The results of genotype and pre-core 
region mutations in relation to response are summarised in Table 2.    
Relaxed circular HBV-DNA viral load in liver  
Median RC HBV-DNA concentration in pre-treatment liver biopsies was 
4.41 log10copies/ng of liver genomic DNA (lg DNA) (range 1.71–5.14) in treated 
patients and tended to be lower in responders than non-responders (3.82, 1.71–
4.18 vs. 4.71, 2.78-5.14 log10copies/ng of lg DNA, p=0.16). The median 
concentration of RC HBV-DNA in untreated patients (4.22, 2.2-5.2 log10copies/ng 
of lg DNA, p=0.45) did not differ from the treated cohort. 
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cccDNA concentration in liver 
The tissue concentration of cccDNA was similar in treated and untreated 
patients (2.08, 0.57-3.56 vs. 1.88, 0.76-3.49 log10copies/ng of lg DNA) and 
tended to be lower in responders than non-responders (1.98, 0.57-3.56 vs. 2.26, 
1.32-2.37 log10copies/ng of lg DNA, p=0.18). Levels of liver RC HBV-DNA and 
liver cccDNA were positively correlated (r=0.67, p=0.04).   
Expression of HBcAg and HBsAg in liver  
HBcAg expression was observed predominantly within the nucleus of 
hepatocytes and was similar between responders and non-responders (8.1, 1.1-
42.5 vs. 10.5, 0.5-83.6 positive cells/1000 hepatocytes, p=0.24). When assessed 
semi-quantitatively, HBcAg nuclear and cytoplasmatic expression was similar in 
all treated patients, whether responders (median nuclear staining 45% and 
median cytoplasmic staining 32.5%) or not (40% and 30%), and in untreated 
HBV+ controls (45% and 30%). In contrast, HBsAg was predominantly expressed 
in the cytoplasm focally associated with membranous staining [2.9 (0-56.9) 
positive cells/1000 hepatocytes] and was significantly lower in responders than 
non-responders [0.5, (0-16) vs. 4.7 (0-56.9) positive cells/1000 hepatocytes, 
p=0.03]. There were positive bivariate correlations between plasma HBsAg levels 
and liver cccDNA (r=0.44, p=0.04), HBcAg liver expression and cccDNA (r=0.41, 
p=0.04) and between pre-treatment plasma HBsAg levels and HBsAg liver 
expression (r=0.38, p=0.05). Testing was not performed in untreated patients.  
Multivariate analysis  
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HBV-DNA load at TW52 (p=0.003), FUW24 (p=0.001) and FUW52 
(p=0.001) and HBsAg plasma levels at TW28 (p=0.001), TW52 (p=0.001) and 
FUW24 (p=0.001) were significantly lower in responders than non-responders. 
 
DISCUSSION  
Loss of HBsAg with anti-HBs seroconversion is the ultimate goal of 
antiviral therapy for chronic hepatitis B infection [3]. The present longitudinal 
study firstly demonstrates the role of HBsAg plasma pre-treatment levels and 
their on-treatment kinetics in predicting therapy response; secondly, it illustrates 
the relationship between pre-treatment liver cccDNA, relaxed circular HBV-DNA 
and liver expression of HBsAg; and thirdly, it highlights the importance of 
changes in BCP and 1896 codon of the pre-core region in relation to therapy 
response (HBsAg loss) in children with immunotolerant perinatally acquired CHB 
infection treated with lead-in lamivudine followed by add-on interferon [45].  
Of the 23 vertically infected patients participating in a pilot treatment study, 
5 (22%) achieved seroconversion to anti-HBs either during treatment or within 1 
year post therapy, reflecting transition from an immune tolerance state to viral 
control [40]. Patients achieving viral control were characterized by lower pre-
treatment HBsAg plasma levels, lower HBsAg expression in the liver, sharper 
decline of HBV-DNA within the first 9 weeks of therapy during the lamivudine 
lead-in phase, followed by a steep decrease in HBsAg plasma levels (>1-
log10IU/ml) by treatment week 28, during the IFN- add-on phase. Although 
concentrations of intrahepatic relaxed circular HBV-DNA and cccDNA tended to 
be lower in responders, HBcAg expression in the liver was similar between 
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responders and non-responders. The therapy response was associated with 
lower cytoplasmic expression of HBsAg in the liver. Plasma HBsAg levels 
correlated with intrahepatic RC HBV-DNA, cccDNA and HBsAg expression within 
the liver reflecting transcriptional activity of intrahepatic viral DNAs.  
Though on-treatment viral kinetics are currently used to monitor treatment 
response and to decide treatment duration in adults with CHB [16-31], data are 
not available in children. In particular there is no information on HBsAg kinetics in 
paediatric immunotolerant patients during antiviral therapy. In our cohort, the 
combination of pre-treatment HBsAg plasma levels <4.3-log10IU/ml and the 
HBsAg kinetics profile, i.e. a decline >1-log10IU/ml, during the first 6 months of 
therapy after adding INF-, was highly predictive of response. Lower HBsAg 
plasma levels at baseline also predict therapy response in adult immunoactive 
patients on therapy with pegylated interferon (Peg-IFN) alone or in combination 
with lamivudine (LAM) commenced simultaneously [18-21-22].  
In a Dutch study investigating the impact of HBsAg plasma levels and their 
on-treatment kinetics during pegylated-interferon ± lamivudine therapy, HBsAg 
<1500 IU/ml (3.17-log10IU/ml) at TW24 predicted HBeAg seroconversion and 
HBV-DNA <2000 IU/ml 6 months after stopping therapy (PPV 54% and NPV 
76%) [22]. Applying these criteria to our paediatric cohort, at TW28 (20 weeks 
after adding IFN-) all five patients who lost HBsAg after therapy had HBsAg 
levels <1000 IU/ml, while none of fifteen patients with an HBsAg decline <1-
log10IU/ml achieved response (NPV 100%).  
In the Dutch study, patients treated with a combination of lamivudine and 
Peg-IFN- 2b achieved a higher and earlier anti-HBe seroconversion rate during 
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treatment and a higher rate of HBsAg loss at follow up than patients treated with 
Peg-IFN- 2b alone [44]. In agreement with these observations, all our patients 
who lost HBsAg had HBeAg seroconversion between the first 12-20 weeks of 
therapy, while two patients who achieved HBeAg seroconversion during the post-
treatment follow-up never lost HBsAg. Therefore, early anti-HBe seroconversion 
heralds treatment-induced complete viral control.  
In our cohort, responders tended to have lower intrahepatic concentrations 
of RC HBV-DNA and cccDNA and a lower expression of HBsAg within the liver. 
Baseline HBsAg plasma levels correlated positively with cccDNA, liver RC HBV-
DNA and liver HBsAg expression akin to what  observed in adult HBeAg+ 
patients, in whom pre-treatment HBsAg plasma levels correlate with liver 
cccDNA and liver HBV-DNA, suggesting that plasma HBsAg levels may act as a 
surrogate marker of cccDNA and intrahepatic relaxed circular HBV-DNA [11,16].  
In our patients, the switch between immune tolerance to immune control 
and HBsAg clearance was linked to a significant reduction of HBV-DNA 
replication initially, followed by a sharp decline in HBsAg production as a likely 
consequence of the immune enhancing effect of IFN-. In the same cohort of 
patients, we have previously shown that combined treatment elicits virus-specific 
immune responses [38]. Thus, HBsAg decline and its kinetics are likely to reflect 
strong and multispecific adaptive immune responses fostering the progression 
from immunotolerance to complete viral control [38]. The predominance of 
genotype B in the responders might contribute to the lower pre-treatment HBsAg 
levels, as there was no difference in HBV-specific reactivity at baseline between 
responders and non-responders [38]. 
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In immunoactive adult patients concentrations of cccDNA and intrahepatic 
RC HBV-DNA have been variably reported to predict HBsAg plasma levels and 
response to treatment [16, 35, 37]. In our cohort of immunotolerant children - a 
yet untested patient population - there was only a tendency for cccDNA and 
relaxed circular DNA tissue levels to be lower in responders than non-
responders, the difference from adult studies probably reflecting the small 
number of our patients, their immunotolerant status and different HBV genotypes.   
Similar to reports in adults  [45], the children who lost HBsAg in our cohort 
had genotypes A or B. In agreement with the report by Sonneveld et al [39], all 
our patients who lost HBsAg had wild type BCP and 1896 codon in the pre-core 
region, while mutations were present in 14 of the 18 non-responders. 
Although the present study is not focused on  therapeutic approaches in 
children with infancy-acquired  infection who are tolerant to HBV , it is important 
to highlight the lack of data in this group of patients. In general, the goal of 
antiviral HBV therapy in children, as in adults, is to improve the long-term survival 
and quality of life by reducing the risk of liver disease progression, preventing the 
development of cirrhosis and hepatocellular carcinoma (HCC)  [3, 46]. Long-term 
high HBV-DNA viral load, as seen during the immunotolerant phase of the 
disease, is an independent risk factor for evolution to cirrhosis and HCC [47]. In 
addition, childbearing female patients in the immunotolerant stage of HBV 
infection  have a  high risk of transmitting the virus  to the next generation.  All 
these factors should be taken into account when designing treatment in 
paediatric patients. There is a limited number of anti-HBV drugs licensed for 
children, in particular in those  younger  than <12 years. Most studies in 
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paediatrics use monotherapy and include children with immunoactive disease. 
There is little information on the treatment of immunotolerant children  [46]. 
However, on the basis of the encouraging results in terms of HBsAg loss of two 
pilot studies using lamivudine/standard interferon combination therapy [40, 51], 
currently two large clinical trials of sequential combination therapy with a 
nucleoside analogue (lamivudine or entecavir) and  pegylated interferon are 
ongoing [48-49].  
 Recently, several pilot adult studies have also focused on a sequential 
combination therapy using  nucleos(t)ide analogues lead-in followed by addition 
of interferon [50-53]. This approach is based on the immunopathology knowledge 
that harnessing the immune response is important to achieve a ‘functional cure’ 
of HBV infection (HBsAg loss). On the one hand, long-term anti-viral therapy with 
a nucelos(t)ide analogue improves  HBV-specific the cytotoxic T lymphocyte 
reactivity, which is a critical component of the anti-HBV response [43,54], on the 
other hand interferon based therapy stimulates innate immune system natural 
killer cell activity, which increases in patients during therapy and persists during 
the post-treatment follow-up period [55]. The concerted action of innate and 
adaptive immune responses  is needed to achieve HBV replication control, 
including that of nuclear cccDNA, and  attain HBsAg loss/anti-HBs 
seroconversion. An additional  effect of pro-inflammatory cytokines on HBV 
replication, namely of IFN-α on the epigenic regulation of the nuclear cccDNA 
minichromosome (critical component of HBV persistence) has been 
demonstrated in-vitro and in animal models [56-57]. 
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High HBV-DNA levels are linked to  high concentrations of viral antigens, 
leading to immune system exhaustion and immune tolerance in the long-term 
[58]. Reduction of the  HBV-DNA viral load with consequent decrease of  HBV 
antigens enhances  the immune system recognition [15]. In our cohort, although 
HBV-DNA declined after 9 weeks of therapy with lamivudine, there were no or 
minimal changes in HBsAg levels between baseline and TW9. Adding interferon 
at TW9 contributed to the HBsAg decline and to the restoration of the immune 
responses in all patients, but more significantly in theresponders, indicating a 
concerted effect of the innate and adaptive immune responses [38]. Whether 
serological immune markers likechemokine and cytokine levels including 
CXCL10, in conjunction with HBV-DNA viral load, HBsAg and HBeAg plasma 
levels and HBsAg subtype (viral vs subviral particles ratio) would be helpful in 
determining the best timing for adding interferon to nucelos(t)ide analogues  
needs to be investigated .   
In conclusion, the present longitudinal study demonstrates that assessment 
of pre-treatment HBsAg plasma levels and monitoring of their on-treatment kinetics 
during combination therapy, in particular during the early phase of add-on 
interferon treatment, are useful tools for predicting therapy response and for 
tailoring treatment in immunotolerant children, as recently advocated for adult 
patients [30-31]. However, a degree of caution should be applied when universally 
implementing these therapy response predictors owing to the genotypic variability 
and variable immunological stages of CHB [24].  Larger combination treatment 
trials of tolerant patients, using sequential therapy with more powerful new 
generation nucleot(s)ide analogues lead-in, to efficiently suppress HBV-DNA and 
 21 
prevent emergence of mutations, followed by pegylated-interferon add-on, are 
warranted to validate the use of these markers in predicting treatment response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
 
Table 1: Patient clinical and laboratory data (median and range) 
 
 Treated 
(N=23) 
Untreated 
(N=7) 
Age  
Median [years] 
Range 
10.2 
2.9–16.8 
9.8 
3.8–14.1 
Gender (Male/Female) 8/15 3/4 
Ethnicity:  
 Caucasian 
 Oriental 
 African 
 Mixed 
 
5 
17 
1 
1 
 
2 
4 
1 
 
Genotype: 
 A 
 B 
 C 
 D 
 E 
 
2 
14 
2 
4 
1 
 
1 
3 
1 
1 
1 
AST [IU/L] 
Median 
Range 
29 
18-90 
32 
22-68 
HBV-DNA [log10IU/ml] 
Median 
Range 
8.17 
7.03-8.90 
8.32 
7.23-8.96 
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AST: aspartate aminotransferase (normal value <50IU/L); 
HBV-DNA: hepatitis B virus DNA 
 
 
 
 
Table 2 
 
Table 2: HBV genotypes and pre-core region mutations 
 
 Treated 
(N=23) 
Untreated 
(N=7) 
 
 
 
 
Responders 
(N=5) 
Non-responders 
(N=18) 
Genotype: 
* A 
* B 
 
* C 
* D 
 
 
* E 
 
1 patient (WT) 
4 patients (WT) 
 
0 patients 
0 patients 
 
 
0 patients 
 
1 patient (A1762T/G1764A) 
7 patients (A1762T/G1764A) 
3 patients (WT) 
2 patients (A1762T/G1764A) 
2 patients (G1896A) 
1 patient (A1762T/G1764A) 
1 patient (WT) 
1 patient (A1762T/G1764A) 
 
1 patient (WT) 
1 patient 
(A1762T/G1764A) 
2 patients (WT) 
1 patient 
(A1762T/G1764A) 
1 patient (WT) 
 
 
1 patient (G1896A) 
 
WT: wild type  
A1762T/G1764A: basal core promoter (BCP) mutations 
G1896A: stop codon 1896 mutation  
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